The need to accelerate access to new drugs for multidrug-resistant tuberculosis
AbstractApproximately half a million people are thought to develop multidrug-resistant tuberculosis annually. Barely 20% of these people currently receive recommended treatment and only about 10% are successfully treated. Poor access to treatment is probably driving the current epidemic, via ongoing...
Saved in:
Main Authors: | Helen S Cox (Author), Jennifer J Furin (Author), Carole D Mitnick (Author), Colleen Daniels (Author), Vivian Cox (Author), Eric Goemaere (Author) |
---|---|
Format: | Book |
Published: |
The World Health Organization,
2015-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Household contact management for rifampicin-resistant tuberculosis
by: Anja Reuter, et al.
Published: (2022) -
Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru
by: Dylan B. Tierney MD MPH, et al.
Published: (2016) -
Principles for designing future regimens for multidrug-resistant tuberculosis
by: Grania Brigden, et al.
Published: (2014) -
Beyond goodwill and promises-urgent needs and opportunities to accelerate the fight against tuberculosis in Brazil
by: Carlos Podalirio Borges de Almeida, et al.
Published: (2024) -
"A very humiliating illness": a qualitative study of patient-centered Care for Rifampicin-Resistant Tuberculosis in South Africa
by: Jennifer Furin, et al.
Published: (2020)